Papers/PMID:32256955
The Beneficial Effects of Alpha Lipoic Acid Supplementation on Lp-PLA2 Mass and Its Distribution between HDL and apoB-Containing Lipoproteins in Type 2 Diabetic Patients: A Randomized, Double-Blind, Placebo-Controlled Trial.
Oxidative medicine and cellular longevity2020The record
1 finding · 1 compound · 1 endpoint
What it reported
How to read these marksWhat moved
1 finding
lipoic acid — decreases triglycerides
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“At the end of the study, TG reduced significantly in the ALA group (P < 0.001) and the significant time to group interaction effect was observed (P = 0.03).”
Quoted verbatim from The Beneficial Effects of Alpha Lipoic Acid Supplementation on Lp-PLA2 Mass and Its Distribution between HDL and apoB-Containing Lipoproteins in Type 2 Diabetic Patients: A Randomized, Double-Blind, Placebo-Controlled Trial.. - Study
- RCT
- Duration
- 8 weeks
- Dose
- 1200 mg ALA per day as two 600 mg capsules, one capsule twice daily 30 minutes before meals
- Population
- Patients with type 2 diabetes, aged 40 to 60 years, HbA1c below 7%, BMI 18.5 to 29.9, on stable metformin, sulfonylurea, statin, ACE inhibitor, ARB or low-dose aspirin therapy
The Beneficial Effects of Alpha Lipoic Acid Supplementation on Lp-PLA2 Mass and Its Distribution between HDL and apoB-Containing Lipoproteins in Type 2 Diabetic Patients: A Randomized, Double-Blind, Placebo-Controlled Trial.2020PMID:32256955Permalink